If You Are an Income Investor, You Will Love These Pharma Companies

Madhukar is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.

Companies know that to attract regular income-seeking investors, it helps to pay out high dividends. At times when treasuries are disappointing with low yields for 10-year T-notes and corporate bonds are offering no respite, the hunger for dividend stocks is higher than ever. Here are three companies in the pharmaceutical industry that are developing new drugs with high earnings potential in the long run. These companies are also generating ample free cash flows to distribute as dividends, and currently have a dividend payout ratio of more than 80%.

<table> <thead> <tr><th> <p><strong>Company</strong></p> </th><th> <p><strong>5-Year Avg. Dividend Yield</strong></p> </th></tr> </thead> <tbody> <tr> <td> <p><strong>GlaxoSmithKline <span class="ticker" data-id="203785">(NYSE: <a href="http://caps.fool.com/Ticker/GSK.aspx">GSK</a>)</span></strong></p> </td> <td> <p>4.70%</p> </td> </tr> <tr> <td> <p><strong>Bristol-Myers Squibb <span class="ticker" data-id="202977">(NYSE: <a href="http://caps.fool.com/Ticker/BMY.aspx">BMY</a>)</span></strong></p> </td> <td> <p>4.60%</p> </td> </tr> <tr> <td> <p><strong>Merck <span class="ticker" data-id="204567">(NYSE: <a href="http://caps.fool.com/Ticker/MRK.aspx">MRK</a>)</span></strong></p> </td> <td> <p>4.40%</p> </td> </tr> </tbody> </table>

Read on to see how these company's strategies will lead to shareholders' wealth maximization.

New drugs for future growth

It is estimated that in the current year, 76,690 American residents will be suffering from melanoma, a type of skin cancer. The FDA approved GlaxoSmithKline's two new drugs Tafinlar and Mekinist to treat melanoma on May 30, 2013. These drugs were tested on approximately 500 patients and showed better results than the company's previous drug, Dacarbazine. Only 15.3% of patients respond to Dacarbazine, but the new drugs will delay cancerous cellular growth that leads to melanoma by approximately three months. It is estimated that Tafinlar and Mekinist will contribute $85.2 million this year to GlaxoSmithKline's revenue, followed by $215 million in 2014.

Chronic airflow limitation, or CAL, is a respiratory disease which limits air passage through lungs. This disease requires a lung transplant and long-term oxygen therapy. GlaxoSmithKline's respiratory franchise has developed a drug called Breo to treat CAL which received FDA approval on May 12, 2013. Breo helps patients' lungs maintain air flow without long-term oxygen therapy or transplantation. The daily dosage of this drug also halts the progression of the disease. Breo will contribute $35 million to the company sales by the end of this year and $370 million in 2014.

Overall, it is expected that the company will earn $26.5 billion this year. It expects free cash flow of $7.3 billion and management will distribute it to the shareholders in accordance with the dividend policy.

Combining drugs for incremental revenue

Bristol-Myers Squibb is taking advantage of its monopoly on the drug Ipilimumab it has enjoyed for two years. This drug is used to cure patients suffering from advanced melanoma, but patients with low white blood cells were not responding to this drug. To correct this, the company added Nivolumab antibodies to Ipilimumab which will help to treat this subset of patients. Bristol-Myers Squibb is the only company making combinations to fight against advanced melanoma. This particular combination will expand the utility of the drug, and with this combination the drug will generate revenue of $905 million this year followed by $1.04 billion in 2014.

One of the company's key drugs, Sprycel, showed an impressive sales growth of 24%, reaching to $287 million in the first quarter of 2013. This drug is used to treat different types of cancers. The company has developed an update to this drug, and the FDA approved its updated labeling of three-year efficacy and safety on June 20, 2013. The drug was updated after tests produced desired results for patients who are Philadelphia chromosome-positive (Ph+), which is an abnormality in the structure of their DNA. The company expects to generate revenue of $1.2 billion this year with the updated Sprycel, up from $1 billion last year. This will be followed by $1.4 billion in 2014.

With the combination and upgrading of drugs, Bristol-Myers Squibb will earn $16.3 billion this year, followed by $17.3 billion in 2014. The company expects free cash flows of $3 billion this year, which the management will distribute to its shareholders with a dividend yield of 3.1%.

Insomnia is big business

Merck spent $400 million developing a new insomnia drug, Suvorexant. The uniqueness of this drug is that it has minimal side effects. This drug contains orexin, a neurotransmitter which regulates wakefulness, appetite and arousal. Unlike other insomnia drugs, this drug reduces or prevents wakefulness instead of inducing sleep. The company expects FDA approval in the second half of 2013, and expects the drug to bring additional revenue of $180 million in 2014 and double in 2015.

Merck also manufactures Gardasil, the only vaccine that is used to prevent cancers caused by human papillomavirus, or HPV, and to prevent four types of HPV. This drug showed double-digit growth last year. The company has developed the next generation of Gardasil – a V503 drug for preventing HPV. The new drug will reduce HPV infection rates in patients by more than 70%, which is higher in comparison to Gardasil. This will have a huge impact on reducing HPV rates in the population, leading to greater future effectiveness in eradicating the disease. Merck expects FDA approval for this drug in the second half of 2013. With this improvement, Gardasil vaccine revenue will increase to $2 billion this year, up from $1.6 billion last year.

With these strategies, the company expects to generate free cash flow of $9 billion this year and will distribute to its shareholders with a dividend yield of 3.7% or more.

Investors' take away

GlaxoSmithKline’s new drugs for melanoma and respiratory disease will bring additional revenue for the company. Its long-term drug development strategy brings additional revenue to the company, which it then uses to pay dividends to its investors.

Bristol-Myers Squibb is showing initiative by combining drugs to cure the patients with lower white blood cell counts. The company is making higher sales as a result.

Merck has developed a new drug for insomnia with minimal side effects and improving its vaccine for human papillomavirus. These improvements will increase the company’s revenue.

These companies will continue to generate good cash flow, which they will utilize for paying dividends. These three stocks are a "buy."

Want more dividend investing ideas?

If you're on the lookout for high-yielding stocks, The Motley Fool has compiled a special free report outlining our nine top dependable dividend-paying stocks. It's called "Secure Your Future With 9 Rock-Solid Dividend Stocks." You can access your copy today at no cost! Just click here.

Madhu Dube has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. Is this post wrong? Click here. Think you can do better? Join us and write your own!

blog comments powered by Disqus